Singh S, et al. - In this nationwide register-based propensity score-matched cohort study, researchers compared the effectiveness and safety of adalimumab and infliximab among biologic-naïve patients with Crohn's disease (CD). They found no significant difference in effectiveness and safety of adalimumab and infliximab in biologic-naïve patients with CD.